Articles tagged with: Velcade


[ by | Apr 20, 2015 5:59 pm | 3 Comments ]
Subcutaneous Velcade Leads To Similar Response Rates, But Fewer Side Effects, Compared To IV Velcade In Newly Diagnosed Multiple Myeloma

Initial results of a German clinical trial confirm pre­vi­ous find­ings that sub­cu­ta­ne­ous (under-the-skin) injections of Velcade for the treat­ment of myeloma lead to fewer side effects – but similar overall response rates – com­pared to intra­ve­nous (IV) infusions of the drug.

The trial results also indicate, however, that IV adminis­tra­tion of Velcade may lead to deeper treat­ment responses when patients are given the drug for a limited number of treat­ment cycles.

The German trial is notable not just because it is the largest study to date that has directly compared sub­cu­ta­ne­ous and …

Read the full story »


[ by | Mar 10, 2015 4:33 pm | Comments Off ]
Hochdosiertes Kyprolis verlängert progressionsfreies Überleben gegenüber Velcade in randomisierter Vergleichsstudie für rezidivierte Myelompatienten

Erste Ergebnisse einer großen, direkten, klinischen Vergleichsstudie zeigen, dass rezidivierte Myelompatienten, die mit hochdosiertem Kyprolis und Dexamethason behandelt wurden, ein doppelt so langes progressionsfreies Überleben hatten im Vergleich zu rezidivierten Patienten, die mit Velcade und Dexamethason behandelt wurden.

Das mittlere progressionsfreie Überleben in der Phase 3-Studie betrug 18,7 Monate bei den mit hoch dosiertem Kyprolis (Carfilzomib) und Dexamethason behandelten Studienteilnehmern im Vergleich zu 9,4 Monaten bei Patienten, die Velcade (Bortezomib) und Dexamethason erhielten.

Die Ergebnisse der so genannten "ENDEAVOR"-Studie wurden am letzten Sonntagabend in einer von Amgen (NASDAQ:AMGN) herausgegebenen Presseinformation …

Read the full story »


[ by | Mar 3, 2015 10:36 pm | 8 Comments ]
High-Dose Kyprolis Extends Progression-Free Survival Versus Velcade In Head-To-Head Relapsed Myeloma Trial

Initial results of a large, head-to-head clinical trial show that relapsed myeloma patients treated with high-dose Kyprolis and dex­a­meth­a­sone had twice the progression-free survival of relapsed patients treated with Velcade and dex­a­meth­a­sone.

Median progression-free survival in the Phase 3 trial was 18.7 months in trial participants treated with high-dose Kyprolis (carfilzomib) and dex­a­meth­a­sone (Decadron), compared to 9.4 months in patients treated with Velcade (bor­tez­o­mib) and dex­a­meth­a­sone.

The results of the so-called “ENDEAVOR” trial were announced this past Sunday evening in a press release issued …

Read the full story »


[ by | Sep 3, 2014 7:39 am | 9 Comments ]
Dyclonine, The Active Ingredient In Sucrets, May Enhance The Anti-Myeloma Activity Of Velcade

Results of a small preclinical study conducted at the Karmanos Cancer Center in Detroit indicate that the oral anesthetic dyclonine may enhance the anti-myeloma activity of Velcade.

Dyclonine is the active ingredient in the Sucrets brand of sore throat lozenges, which are sold over-the-counter in drugstores and other retailers in Canada and the United States.  Sucrets lozenges are marketed by Insight Pharmaceuticals.

The Karmanos researchers conducted laboratory tests of dyclonine's activity against the so-called "RPMI8226" line of myeloma cells, which is commonly used in pre-clinical testing of potential myeloma therapies. …

Read the full story »


[ by | Jul 16, 2014 8:54 am | 41 Comments ]
Treatment Regimen Featuring Revlimid-Velcade-Dexamethasone Therapy And Stem Cell Transplantation Yields Deep Responses In Newly Diagnosed Multiple Myeloma

French researchers earlier this week published updated results of a small Phase 2 clinical trial testing the combination of Revlimid, Velcade, and dexa­metha­sone (RVD) in newly diagnosed multiple myeloma pa­tients.

The researchers found that RVD, when given before and after stem cell trans­plan­ta­tion – and when followed by maintenance therapy with Rev­limid – led to very deep treatment responses and significant survival rates.

The 31 newly diagnosed patients in the French trial initially were treated with three cycles of RVD therapy.  Next, the trial participants underwent autologous (own) stem cell …

Read the full story »